Idelalisib

Recurrent Acute Myeloid Leukemia

OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant

CCC

49/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 34/ 100
Competitive Position: 89/ 100

Competitive context

23 Active assets in the Recurrent Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Ipilimumab OHSU Knight Cancer Institute	Phase 2	B
gsk1120212 M.D. Anderson Cancer Center	Phase 2	B
Enasidenib Children's Oncology Group	Phase 2	B
Olaparib National Cancer Institute (NCI)	Phase 2	B
Solu-Cortef Children's Oncology Group	Phase 2	B

View all 50 →

Same molecule, other indications

Idelalisib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

B

Indicative ·

59 / 100

lymphoplasmacytic lymphomaDormant

B

Indicative ·

57 / 100

marginal zone lymphomaDormant

B

Indicative ·

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.